<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03552276</url>
  </required_header>
  <id_info>
    <org_study_id>CLR_18_07</org_study_id>
    <nct_id>NCT03552276</nct_id>
  </id_info>
  <brief_title>A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.</brief_title>
  <official_title>A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharma Global FZE</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharma Global FZE</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A long term study to demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With
      Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 11, 2018</start_date>
  <completion_date type="Anticipated">August 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This long-term extension study will remain double-blind or partially blinded for subjects from the parent studies reach at a stage of either database lock or a certain pre-specified time period, and then the study will be open-blind for the subjects.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>4 years</time_frame>
    <description>Incidence and intensity of adverse events will be assessed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving a 20% reduction from Baseline in American College of Rheumatology response criteria</measure>
    <time_frame>4 years</time_frame>
    <description>Improvement from Baseline in both tender joints and swollen joints will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">540</enrollment>
  <condition>Psoriatic Arthritis</condition>
  <condition>Ankylosing Spondylitis</condition>
  <condition>Non-Radiographic Axial Spondyloarthritis</condition>
  <arm_group>
    <arm_group_label>tildrakizumab 200 mg q4 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Psoriatic arthritis subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tildrakizumab 200 mg q12 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Psoriatic arthritis subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg q12 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Psoriatic arthritis (PsA) subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tildrakizumab 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis (AS/nr-axSpA) subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tildrakizumab 200 mg (two 1-mL injections of 100 mg/mL)</intervention_name>
    <description>at Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44,48, 52, and all subsequent 4-weekly time points to Week 200.</description>
    <arm_group_label>tildrakizumab 200 mg q4 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tildrakizumab 200 mg (two 1-mL injections of 100 mg/mL)</intervention_name>
    <description>at Weeks 8, 20, 32, 44, 56, and all subsequent 12-weekly time points to Week 200, as well as placebo (two 1-mL injections) at interim 4-weekly time points commencing at Baseline of the Phase 2 parent study to Week 196.</description>
    <arm_group_label>tildrakizumab 200 mg q12 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tildrakizumab 100 mg (one 1-mL injection of 100 mg/mL + 1 mL placebo)</intervention_name>
    <description>at Weeks 8, 20, 32, 44, 56, and all subsequent 12-weekly time points to Week 200, as well as placebo (two 1-mL injections) at interim 4-weekly time points commencing at Baseline of the Phase 2 parent study to Week 196.</description>
    <arm_group_label>100 mg q12 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tildrakizumab 200 mg (two 1-mL injections of 100 mg/mL)</intervention_name>
    <description>at Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and all subsequent 4-weekly time points to Week 200.</description>
    <arm_group_label>tildrakizumab 200 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject has provided written informed consent for this long-term extension study.

          2. Subjects with psoriatic arthritis (PsA) and ankylosing spondylitis (AS) or
             non-radiographic axial spondyloarthritis (nr-axSpA) who met the inclusion criteria of
             the parent studies and completed the parent study treatment period (e.g., up to Week
             48 for the parent Phase 2 studies, with the return for the end of treatment (EoT)
             assessment at Week 52).

          3. PsA subjects who achieved a 20% reduction from Baseline in ACR20 response criteria at
             Week 52, and AS or nr-axSpA subjects who achieved ASAS40 response criteria at Week 52,
             AND the subject has received sufficient clinical benefit, in the opinion of the
             Investigator, to support continued treatment with tildrakizumab. These criteria using
             response criteria at Week 52 will apply to all subjects, including those subjects who
             enter the study from the wash-out phase of their parent study (after Week 52) due to
             the timing of study site activation of the long-term extension study.

          4. No concomitant use of both leflunomide and methotrexate, No history of active
             tuberculosis (TB) or symptoms of TB.

        Exclusion Criteria:

          1. New onset during the parent study of arthritic conditions other than the subject's
             original condition.

          2. Female subjects of childbearing potential who do not agree to abstain from
             heterosexual activity or practice a dual method of contraception, for example, a
             combination of the following: (1) oral contraceptive, depo-progesterone, or
             intrauterine device; and (2) a barrier method (condom or diaphragm). Male subjects
             with female partners of childbearing potential who are not using birth control as
             described above must use a barrier method of contraception (e.g., condom) if not
             surgically sterile (i.e., vasectomy). Contraceptive methods must be practised upon
             entering the study and through 16 weeks after the last dose of IMP. If a subject
             discontinues prematurely, the contraceptive method must be practised for 16 weeks
             following final administration of IMP.

          3. Female is pregnant or breastfeeding, or planning to become pregnant or initiate
             breastfeeding while enrolled in the study or up to 16 weeks after the last dose of
             IMP.

          4. Subject has previously been enrolled in this long-term extension study.

          5. Any condition that in the opinion of the Investigator represents an obstacle for study
             conduct and/or represents a potential unacceptable risk for the subject.

          6. Subject has an active infection or history of infections as follows:

               -  a serious infection, defined as requiring hospitalization or intravenous
                  anti-infectives within 8 weeks prior to the first IMP dose of the extension
                  study, with the last dose having been received within 7 days of start of the
                  extension study,

               -  recurrent or chronic infections, e.g., chronic pyelonephritis, chronic
                  osteomyelitis, bronchiectasis, or other active infection that, in the opinion of
                  the Investigator, might cause this extension study to be detrimental to the
                  subject.

          7. Major chronic inflammatory or connective tissue disease other than PsA or AS/nr axSpA
             (e.g., rheumatoid arthritis, systemic lupus erythematosus, Lyme disease, and gout).

          8. Known diagnosis of fibromyalgia, regional pain syndromes or active uveitis/symptomatic
             inflammatory bowel disease requiring therapy (AS/nr-axSpA subjects),

          9. Subject has any concurrent medical condition or uncontrolled, clinically significant
             systemic disease (e.g., renal failure, heart failure, hypertension, liver disease,
             diabetes, or anaemia) that, in the opinion of the Investigator, could cause continued
             treatment to be detrimental to the subject.

         10. Subject has a known history of infection with hepatitis B, hepatitis C, or human
             immunodeficiency virus during the parent study.

         11. Subject had a myocardial infarction, unstable angina pectoris, or ischemic stroke
             within the past 6 months prior to the first IMP dose for this extension study.

         12. Subject has any active malignancy, including evidence of cutaneous basal or squamous
             cell carcinoma or melanoma.

         13. Subject has a history of malignancy EXCEPT treated and considered cured cutaneous
             basal or squamous cell carcinoma, in situ cervical carcinoma, OR in situ breast ductal
             carcinoma.

         14. Subjects with a history of alcohol or drug abuse during the parent study.

         15. Significant risk of suicidality at the Baseline assessment of this extension study
             based on the Investigator's judgment or, if appropriate, as indicated by a response of
             &quot;yes&quot; since the last visit to question 4 or 5 in the suicidal section, or any response
             in the behavioral section of the Columbia-Suicide Severity Rating Scale (C SSRS).

         16. Subject has a need for use of a live vaccine within 10 weeks of final anticipated dose
             of IMP for the long-term extension study.

         17. Concomitant use of prohibited medications or use of commercially available or
             investigational biologic therapies (other than tildrakizumab) for psoriasis, PsA,
             and/or AS/nr axSpA.

             General:

         18. Subjects who have been placed in an institution on official or judicial orders.

         19. Subjects who are related to or dependent on the Investigator, Sponsor, or study site
             such that a conflict of interest may arise.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Site 25</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 15</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 16</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 28</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 14</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 81</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 27</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 23</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 20</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 26</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 24</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 19</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 17</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 18</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 21</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 22</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 02</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1128AAF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 01</name>
      <address>
        <city>Mar Del Plata</city>
        <state>Buenos Aires</state>
        <zip>7600</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 03</name>
      <address>
        <city>San Fernando</city>
        <state>Buenos Aires</state>
        <zip>1646</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 80</name>
      <address>
        <city>Córdoba</city>
        <state>Cordoba</state>
        <zip>X5000JHQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 30</name>
      <address>
        <city>Budapest</city>
        <zip>1023</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 32</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 34</name>
      <address>
        <city>Budapest</city>
        <zip>1062</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 33</name>
      <address>
        <city>Kistarcsa</city>
        <zip>2143</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 29</name>
      <address>
        <city>Nyíregyháza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 31</name>
      <address>
        <city>Szolnok</city>
        <zip>5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 09</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 05</name>
      <address>
        <city>Mexico City</city>
        <state>Mexico, City</state>
        <zip>7760</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 06</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 13</name>
      <address>
        <city>San Luis Potosí</city>
        <state>San Luis Potosi</state>
        <zip>78213</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 04</name>
      <address>
        <city>San Luis Potosí</city>
        <state>San Luis Potosi</state>
        <zip>78220</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 07</name>
      <address>
        <city>Culiacán</city>
        <state>Sinaloa</state>
        <zip>80000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 12</name>
      <address>
        <city>Mérida</city>
        <state>Yucatan</state>
        <zip>97070</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 11</name>
      <address>
        <city>Chihuahua</city>
        <zip>31000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 08</name>
      <address>
        <city>Cuautitlán Izcalli</city>
        <zip>54769</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 10</name>
      <address>
        <city>Durango</city>
        <zip>34080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 45</name>
      <address>
        <city>Kraków</city>
        <state>Malopolskie</state>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 35</name>
      <address>
        <city>Elbląg</city>
        <state>Warminsko-Mazurskie</state>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 44</name>
      <address>
        <city>Białystok</city>
        <zip>15-099</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 38</name>
      <address>
        <city>Białystok</city>
        <zip>15-879</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 47</name>
      <address>
        <city>Bytom</city>
        <zip>41-902</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 36</name>
      <address>
        <city>Elbląg</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 39</name>
      <address>
        <city>Katowice</city>
        <zip>40-081</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 40</name>
      <address>
        <city>Katowice</city>
        <zip>40-282</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 46</name>
      <address>
        <city>Kraków</city>
        <zip>30-002</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 37</name>
      <address>
        <city>Lublin</city>
        <zip>20-607</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 48</name>
      <address>
        <city>Nowa Sól</city>
        <zip>67-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 42</name>
      <address>
        <city>Poznan</city>
        <zip>60-848</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 41</name>
      <address>
        <city>Poznań</city>
        <zip>61-397</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 53</name>
      <address>
        <city>Sochaczew</city>
        <zip>96-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 50</name>
      <address>
        <city>Warszawa</city>
        <zip>02-691</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 52</name>
      <address>
        <city>Warszawa</city>
        <zip>04-305</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 51</name>
      <address>
        <city>Wrocław</city>
        <zip>51-685</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 49</name>
      <address>
        <city>Wrocław</city>
        <zip>52-416</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 43</name>
      <address>
        <city>Łódź</city>
        <zip>90-265</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 61</name>
      <address>
        <city>Kemerovo</city>
        <state>Kemerovo Region</state>
        <zip>650066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 58</name>
      <address>
        <city>Novosibirsk</city>
        <state>Novosibirsk Oblast</state>
        <zip>630099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 63</name>
      <address>
        <city>Petrozavodsk</city>
        <state>Republic Of Karelia</state>
        <zip>185019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 54</name>
      <address>
        <city>Tomsk</city>
        <state>Tomsk Oblast</state>
        <zip>634050</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 56</name>
      <address>
        <city>Izhevsk</city>
        <zip>426077</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 82</name>
      <address>
        <city>Kursk</city>
        <zip>305007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 60</name>
      <address>
        <city>Moscow</city>
        <zip>115404</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 57</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>196084</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 62</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 55</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 59</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 69</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 67</name>
      <address>
        <city>Santiago De Compostela</city>
        <state>La Coruna</state>
        <zip>15702</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 65</name>
      <address>
        <city>Málaga</city>
        <state>Malaga</state>
        <zip>29730</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 68</name>
      <address>
        <city>Bilbao</city>
        <state>Vizcaya</state>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 66</name>
      <address>
        <city>Barcelona</city>
        <zip>08034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 64</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 70</name>
      <address>
        <city>Santiago De Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 71</name>
      <address>
        <city>Sevilla</city>
        <zip>41010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 75</name>
      <address>
        <city>Kharkiv</city>
        <zip>61039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 73</name>
      <address>
        <city>Kiev</city>
        <zip>03151</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 74</name>
      <address>
        <city>Kyiv</city>
        <zip>01023</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 76</name>
      <address>
        <city>Kyiv</city>
        <zip>02091</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 72</name>
      <address>
        <city>Kyiv</city>
        <zip>03110</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 77</name>
      <address>
        <city>Odesa</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 83</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 79</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 78</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Hungary</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 4, 2018</study_first_submitted>
  <study_first_submitted_qc>June 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2018</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

